S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
Log in
OTCMKTS:NSPX

Inspyr Therapeutics Stock Forecast, Price & News

$0.02
0.00 (0.00 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.02
Now: $0.02▼
$0.02
50-Day Range
$0.01
MA: $0.01▼
$0.04
52-Week Range
$0.00
Now: $0.02▼
$1.13
Volume4.69 million shs
Average Volume28.79 million shs
Market Capitalization$2.85 million
P/E RatioN/A
Dividend YieldN/A
Beta-16.55
Inspyr Therapeutics, Inc., clinical-stage pharmaceutical company, focuses on the development of therapeutics for the treatment of diseases. It focuses on a pipeline of small molecule adenosine receptor modulators, such as A2B antagonists, dual A2A/A2B antagonists, and A2A agonists. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was founded in 2003 and is based in Westlake Village, California.

Headlines

Inspyr Therapeutics, Inc.: Inspyr Therapeutics Further Strengthens Global Intellectual Property
February 18, 2021 |  finanznachrichten.de
Inspyr Therapeutics Further Strengthens Global Intellectual Property
February 18, 2021 |  finance.yahoo.com
Inspyr Therapeutics, Inc.: Inspyr Therapeutics Secures $500,000 to Support the Development of its Adenosine Pipeline
January 12, 2021 |  finanznachrichten.de
Inspyr Therapeutics Secures $500,000 to Support the Development of its Adenosine Pipeline
January 12, 2021 |  finance.yahoo.com
Inspyr Therapeutics, Inc.: Inspyr Therapeutics Strengthens Global Intellectual Property
December 11, 2020 |  finanznachrichten.de
Inspyr Therapeutics Strengthens Global Intellectual Property
December 10, 2020 |  finance.yahoo.com
Inspyr Therapeutics, Inc.: Inspyr Therapeutics Reports 2020 Third Quarter Results and Business Update
November 25, 2020 |  finanznachrichten.de
Inspyr Therapeutics Reports 2020 Third Quarter Results and Business Update
November 24, 2020 |  finance.yahoo.com
Inspyr Therapeutics, Inc.: Inspyr Therapeutics Acquires a Novel Immuno-Onoclogy Precision Targeting Platform for the Treatment of Cancer
October 10, 2020 |  finanznachrichten.de
Inspyr reacquires a novel immuno-onoclogy precision from Ridgeway
October 8, 2020 |  seekingalpha.com
Inspyr Therapeutics Inc.
May 26, 2020 |  www.barrons.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NSPX
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.genspera.com
Phone818-661-6302
Employees1
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value($14.05) per share
Price / Book0.00

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-930,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-298.11%

Miscellaneous

Outstanding Shares150,000,000
Market Cap$2.85 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.48 out of 5 stars

Medical Sector

1574th out of 1,956 stocks

Pharmaceutical Preparations Industry

673rd out of 769 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.02
0.00 (0.00 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NSPX News and Ratings via Email

Sign-up to receive the latest news and ratings for NSPX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Inspyr Therapeutics (OTCMKTS:NSPX) Frequently Asked Questions

What stocks does MarketBeat like better than Inspyr Therapeutics?

Wall Street analysts have given Inspyr Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Inspyr Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Inspyr Therapeutics?

Inspyr Therapeutics saw a increase in short interest in the month of January. As of January 29th, there was short interest totaling 158,400 shares, an increase of 161.0% from the January 14th total of 60,700 shares. Based on an average trading volume of 31,473,600 shares, the days-to-cover ratio is presently 0.0 days.
View Inspyr Therapeutics' Short Interest.

How were Inspyr Therapeutics' earnings last quarter?

Inspyr Therapeutics, Inc. (OTCMKTS:NSPX) posted its earnings results on Monday, August, 14th. The company reported ($0.35) earnings per share for the quarter.
View Inspyr Therapeutics' earnings history.

How has Inspyr Therapeutics' stock price been impacted by COVID-19?

Inspyr Therapeutics' stock was trading at $0.0019 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NSPX stock has increased by 826.3% and is now trading at $0.0176.
View which stocks have been most impacted by COVID-19.

Who are Inspyr Therapeutics' key executives?

Inspyr Therapeutics' management team includes the following people:
  • Mr. Michael Cain, Interim CEO, CFO, Pres & Exec. Director (Age 37)
  • Dr. John T. Isaacs, Co-Founder, Chairman of Scientific Advisory Board & Chief Scientific Advisor
  • Dr. Samuel R. Denmeade, Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board

Who are some of Inspyr Therapeutics' key competitors?

Some companies that are related to Inspyr Therapeutics include NTN Buzztime (NTN), Tower One Wireless (TOWTF), Acerus Pharmaceuticals (TRLPF), ULURU (ULUR), Parnell Pharmaceuticals (PARNF), Nexien BioPharma (NXEN), Acura Pharmaceuticals (ACUR), American Bio Medica (ABMC), International Stem Cell (ISCO), Kaya (KAYS), Intellipharmaceutics International (IPCIF), Wellness Center USA (WCUI), Cotinga Pharmaceuticals (COTQF), Amarantus BioScience (AMBS) and Helix BioMedix (HXBM).
View all of NSPX's competitors.

What other stocks do shareholders of Inspyr Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inspyr Therapeutics investors own include Hon Hai Precision Industry (HNHPF), iBio (IBIO), Knight-Swift Transportation (KNX), Danaher (DHR), Co-Diagnostics (CODX), Creative Medical Technology (CELZ), Cleveland BioLabs (CBLI), Cloudcall Group (CALL), Blink Charging (BLNK) and BIO-key International (BKYI).

What is Inspyr Therapeutics' stock symbol?

Inspyr Therapeutics trades on the OTCMKTS under the ticker symbol "NSPX."

How do I buy shares of Inspyr Therapeutics?

Shares of NSPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inspyr Therapeutics' stock price today?

One share of NSPX stock can currently be purchased for approximately $0.02.

How much money does Inspyr Therapeutics make?

Inspyr Therapeutics has a market capitalization of $2.64 million.

How many employees does Inspyr Therapeutics have?

Inspyr Therapeutics employs 1 workers across the globe.

What is Inspyr Therapeutics' official website?

The official website for Inspyr Therapeutics is www.genspera.com.

Where are Inspyr Therapeutics' headquarters?

Inspyr Therapeutics is headquartered at 31200 VIA COLINAS SUITE 200, WESTLAKE VILLAGE CA, 91362.

How can I contact Inspyr Therapeutics?

Inspyr Therapeutics' mailing address is 31200 VIA COLINAS SUITE 200, WESTLAKE VILLAGE CA, 91362. The company can be reached via phone at 818-661-6302 or via email at [email protected]


This page was last updated on 2/26/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.